 Home > Active Ingredient News > Blood System > NEJM: Polatuzumab Vedotin for Treatment-naïve Diffuse Large B-Cell Lymphoma

NEJM: Polatuzumab Vedotin for Treatment-naïve Diffuse Large B-Cell Lymphoma

 Last Update: 2022-03-05
 Source: Internet
 Author: User

Tags

tissue cell

cell permeabilization

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Diffuse large B-cell lymphoma (DLBCL) is usually treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
.

However, the R-CHOP regimen can only cure 60% of patients, and about 40% of patients will develop r/r DLBCL

lymphoma stem cells

Polatuzumab vedotin, an antibody-drug conjugate targeting CD79b, which is widely expressed on the surface of malignant B cells, has been approved by the FDA in combination with bendamustine and rituximab for the treatment of r/r DLBCL
.

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b FDA

This study is a double-blind, placebo-controlled, international phase 3 clinical trial to evaluate a modified R-CHOP regimen (pola-R-CHOP: vincristine replaced by Polatuzumab vedotin) versus standard R-CHOP - Therapeutic effect of CHOP regimen compared to previously untreated patients with intermediate-high-risk DLBCL
.

Subjects aged 18-80 were randomized (1:1) to receive 6 courses of pola-R-CHOP or R-CHOP in combination with two courses of rituximab (alone)

2-year progression-free survival

Overall, a total of 879 patients were randomized into two groups: 440 in the pola-R-CHOP group and 439 in the R-CHOP group
.

After a median follow-up of 28.

The 2-year progression-free survival rates in the pola-R-CHOP and R-CHOP groups were 76.

2-year overall survival

In conclusion, among patients with previously untreated intermediate-to-high-risk DLBCL, patients treated with the modified pola-R-CHOP regimen had a relatively lower risk of disease progression, recurrence, and death compared with the standard R-CHOP regimen

Among previously untreated patients with intermediate-to-high risk DLBCL, patients treated with the modified pola-R-CHOP regimen had a relatively lower risk of disease progression, recurrence, and death compared with the standard R-CHOP regimen.

Original source:

Hervé Tilly, et al.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Pharmaceutical Grade 99% 2-Deoxy-D-ribose CAS: 533-67-5 Best Quality

CAS No.: 533-67-5

Pharmacy Grade;

$385-465/KG FOB

Best Quality 99% Semaglutide Semaglutide, Reta, AOD CAS:910463-68-2/782487-28-9 for Weight Loss

CAS No.: 910463-68-2

Pharmacy Grade;

$250-280/G FOB

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$200-250/G FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.